Want to see AU:BP8 full AI Analyst Report?
BP8 Stock Chart & Stats
AU$0.01
AU$0.00(0.00%)
At close: 4:00 PM EDT
AU$0.01
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.02
Previous CloseN/A
Volume0.00
Average Volume (3M)275.38K
Market Cap
AU$3.06M
Enterprise ValueAU$3.67
Total Cash (Recent Filing)AU$259.88K
Total Debt (Recent Filing)AU$555.74K
Price to Earnings (P/E)―
Beta-0.40
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding235,350,170
10 Day Avg. Volume275,377
30 Day Avg. Volume275,377
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-3.09
Price to Sales (P/S)0.78
P/FCF Ratio-1.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sharp Revenue ReboundThe substantial revenue rebound indicates materially improved commercial traction and provides a larger base from which the company could develop recurring sales. If maintained, this expansion may improve operating scale and strengthen the potential for future margin recovery.
Expanded Asset BaseA larger reported asset base suggests the company has expanded its operating resources alongside the revenue rebound. While asset growth has not yet translated into profitability, it may support broader commercial activity and provide greater capacity for future business development.
Improving Free Cash Flow TrendFree cash flow remains negative, but the improvement versus FY2025 indicates some progress in the direction of cash generation. Further improvement would reduce reliance on external funding and could eventually create greater flexibility to support operations and growth.
Bears Say
Negative Shareholders' EquityPersistently negative equity signals significant financial strain and limits balance-sheet flexibility. It can increase recapitalization risk, constrain the company’s ability to fund expansion internally, and amplify the consequences of continued operating losses over the coming quarters.
Sustained Cash BurnOngoing negative operating and free cash flow means the business is not yet funding its activities from internally generated cash. Continued cash burn can force reliance on external funding, reduce strategic flexibility, and make execution more vulnerable if losses persist.
Unprofitable Revenue GrowthThe revenue rebound has not yet produced sustainable economics because gross profit remains negative and losses continue. Without evidence of margin improvement, higher sales may fail to translate into stronger cash generation or a durable path toward profitability.
Stemcell United Ltd. News
BP8 FAQ
What was Stemcell United Ltd.’s price range in the past 12 months?
Stemcell United Ltd. lowest share price was AU$0.01 and its highest was AU$0.02 in the past 12 months.
What is Stemcell United Ltd.’s market cap?
Stemcell United Ltd.’s market cap is AU$3.06M.
When is Stemcell United Ltd.’s upcoming earnings report date?
Stemcell United Ltd.’s upcoming earnings report date is Mar 04, 2027 which is in 158 days.
How were Stemcell United Ltd.’s earnings last quarter?
Stemcell United Ltd. released its earnings results on Aug 31, 2026. The company reported -AU$0.004 earnings per share for the quarter.
Is Stemcell United Ltd. overvalued?
According to Wall Street analysts Stemcell United Ltd.’s price is currently Overvalued.
Does Stemcell United Ltd. pay dividends?
Stemcell United Ltd. does not currently pay dividends.
What is Stemcell United Ltd.’s EPS estimate?
Stemcell United Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Stemcell United Ltd. have?
Stemcell United Ltd. has 235,350,170 shares outstanding.
What happened to Stemcell United Ltd.’s price movement after its last earnings report?
Stemcell United Ltd. reported an EPS of -AU$0.004 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Stemcell United Ltd.?
Currently, no hedge funds are holding shares in AU:BP8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stemcell United Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
176.07%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Stemcell United Ltd.
BPH Global Ltd, along with its associated entities, specializes in the procurement, production, promotion, and sale of traditional medicinal items. Its operational reach spans Australia, Singapore, China, and the broader Southeast Asian market. The company's diverse product range features both unprocessed and refined bird's nest offerings, alongside marine botanicals like Caulerpa Lentillifera (sea grapes) and various seaweeds. These products are utilized across multiple industries, including food, nutrition, healthcare, dietary supplements, cosmetics, and personal care. Headquartered in Melbourne, Australia, the company was founded in 1984 and transitioned to its current name, BPH Global Ltd, in June 2023, having previously been known as Stemcell United Limited.
Technical Analysis
Cynata Therapeutics Limited
―
Living Cell Technologies
―
Mesoblast Limited
―
Orthocell Ltd
―
Regeneus Ltd.
―